Breaking: Medicare will negotiate Ozempic and Wegovy prices

The drugs are on a list of 15 whose prices will be negotiated this year in a program created by the Inflation Reduction Act

Log In    Subscribe BREAKING NEWS   Medicare announces plan to negotiate prices of diabetes, weight loss drugs By Rachel Cohrs Zhang Scott Olson/Getty Images Medicare officials announced that blockbuster diabetes and weight loss treatments Ozempic and Wegovy are now on a list of 15 drugs whose prices will be negotiated this year as a result of President Biden's Inflation Reduction Act.   Now, the choices facing the incoming Trump administration over weight loss drug coverage have massive consequences for the Medicare program, for patients, and for Novo Nordisk, which makes the drugs. READ MORE Sign up for D.C. Diagnosis Washington never stops. Cut through the noise with our essential updates on health care politics and policy. Learn more. In Case You Missed It Generic GLP-1 drugs could help Medicare drive a harder bargain for Ozempic and Wegovy By John Wilkerson In debate over obesity medications, FDA shifts toward importance of drugs in subtle ways By Elaine Chen Inside RFK Jr.'s financials: Biotech investment, health care consulting, 'author introductions' By Isabella Cueto Eli Lilly is considering offering more Zepbound doses in vials at lower cost By Elaine Chen Don't miss out on another STAT Investigation Unlock the world of health and medicine with a subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us